Enrich Therapeutics has been awarded a 24-month Small Business Innovation Research phase II grant in the amount of $1.7 million from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for further development of its proprietary single cell isolation platform.
Enrich proprietary technology targets the huge cell isolation market valued at more than $6 billion in 2020.